imatinib mesylate has been researched along with Bile Duct Cancer in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brivio, S; Cadamuro, M; Cristina Malerba, M; Dall'Olmo, L; Fabris, L; Fingas, C; Fiorotto, R; Indraccolo, S; Mariotti, V; Massani, M; Mertens, J; Milani, C; Milani, E; Moncsek, A; Nardo, G; Spirli, C; Stecca, T; Strazzabosco, M; Vismara, M | 1 |
| Bassi, N; Cadamuro, M; Colledan, M; Dall'olmo, L; Fabris, L; Fiorotto, R; Franceschet, I; Indraccolo, S; Massani, M; Morton, S; Moserle, L; Nardo, G; Sambado, L; Spirli, C; Stecca, T; Strazzabosco, M | 1 |
| Hayakumo, T; Ikura, Y; Iwai, Y; Kadota, C; Shigaki, Y | 1 |
| Guo, RP; Guo, ZX; Lao, XM; Li, JQ; Wang, GH; Ye, ZY; Zhang, YQ | 1 |
| Kluge, R; Mössner, J; Roth, A; Schleyer, E; Schoppmeyer, K; Wiedmann, M; Wittekind, C | 1 |
| Gu, M; Holcombe, RF; Imagawa, D; Milovanovic, T | 1 |
| Bronk, SF; Chiorean, MV; Gores, GJ; Guicciardi, ME; Kaufmanns, SH; Yoon, JH | 1 |
| Blüthner, T; Caca, K; Kamenz, T; Mössner, J; Tannapfel, A; Wiedmann, M | 1 |
1 trial(s) available for imatinib mesylate and Bile Duct Cancer
| Article | Year |
|---|---|
Imatinib mesylate for palliative second-line treatment of advanced biliary tract cancer: a bicentric phase II study.
Topics: Aged; Antineoplastic Agents; Benzamides; Bile Duct Neoplasms; Cholangiocarcinoma; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Gallbladder Neoplasms; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Staging; Palliative Care; Piperazines; Prospective Studies; Pyrimidines | 2011 |
7 other study(ies) available for imatinib mesylate and Bile Duct Cancer
| Article | Year |
|---|---|
Platelet-derived growth factor-D enables liver myofibroblasts to promote tumor lymphangiogenesis in cholangiocarcinoma.
Topics: Animals; Bile Duct Neoplasms; Cancer-Associated Fibroblasts; Cell Line, Tumor; Cholangiocarcinoma; Disease Models, Animal; Endothelial Cells; Heterografts; Humans; Imatinib Mesylate; Liver; Lymphangiogenesis; Lymphokines; Male; Mice; Mice, SCID; Myofibroblasts; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Rats; Rats, Inbred F344; Receptor, Platelet-Derived Growth Factor beta; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor C | 2019 |
Platelet-derived growth factor-D and Rho GTPases regulate recruitment of cancer-associated fibroblasts in cholangiocarcinoma.
Topics: Animals; Antineoplastic Agents; Benzamides; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cells, Cultured; Cholangiocarcinoma; Epithelial-Mesenchymal Transition; Fibroblasts; Heterografts; Humans; Imatinib Mesylate; In Vitro Techniques; Lymphokines; Male; Mice; Mice, SCID; Piperazines; Platelet-Derived Growth Factor; Pyrimidines; rho GTP-Binding Proteins; Signal Transduction | 2013 |
Unexpected DOG-1 immunoreactivity in sarcomatous carcinoma of the liver: a diagnostic pitfall.
Topics: Aged; Anoctamin-1; Antineoplastic Agents; Autopsy; Bile Duct Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Chloride Channels; Diagnosis, Differential; Fatal Outcome; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver; Liver Neoplasms; Male; Neoplasm Proteins; Sarcoma; Tomography, X-Ray Computed; Ultrasonography | 2014 |
A gastrointestinal stromal tumor of the jejunum associated with intrahepatic cholangiocarcinoma and pulmonary hamartoma: a case report.
Topics: Antineoplastic Agents; Benzamides; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Gastrointestinal Stromal Tumors; Hamartoma; Humans; Imatinib Mesylate; Jejunal Neoplasms; Lung Diseases; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2009 |
Expression of Kit and platelet-derived growth factor receptors alpha and beta in cholangiocarcinoma, and case report of therapy with imatinib mesylate (STI571).
Topics: Antineoplastic Agents; Benzamides; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Female; Gene Expression; Humans; Imatinib Mesylate; Middle Aged; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta | 2003 |
Imatinib mesylate induces apoptosis in human cholangiocarcinoma cells.
Topics: Analysis of Variance; Apoptosis; Benzamides; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Caspases; Cholangiocarcinoma; Epidermal Growth Factor; Female; Humans; Imatinib Mesylate; Immunoblotting; Male; Mitochondria; Piperazines; Probability; Pyrimidines; Sensitivity and Specificity; Tumor Cells, Cultured | 2004 |
Expression of c-kit receptor in human cholangiocarcinoma and in vivo treatment with imatinib mesilate in chimeric mice.
Topics: Animals; Antineoplastic Agents; Benzamides; Bile Duct Neoplasms; Cell Line, Tumor; Cholangiocarcinoma; Disease Models, Animal; Female; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Mice; Mice, Nude; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines | 2006 |